News

Earlier in 2014, a Final Appraisal Determination (FAD) was issued, which concluded Lemtrada is a cost-effective use of NHS resources for MS treatment, and formed the basis of

MGD010 incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting (DART) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. Currently, MGD010 is in pre-clinical development for

The evaluation of BMS’ investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, will be done in a Phase I/II trial. Multiple tumor

Probodies are monoclonal antibodies that are selectively activated within the cancer microenvironment, focusing the activity of therapeutic antibodies to tumors and sparing healthy tissue. The unique selectivity of

The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to an earlier patent

These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications. Cellceutix will be shipping the compounds to the university laboratories in the coming

TECFIDERA is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA is indicated as monotherapy for the treatment of RRMS to reduce the frequency of

BioInvent has successfully manufactured ADC-1013 (a FIND optimized n-CoDeR antibody) and will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to

As part of the agreement, the firms have announced the launch of Pamorelin in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Under the